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ABSTRACT Cryptococcus spp. are important fungal pathogens that represent a major cause of morbidity andmortality in both
immunocompetent and immunodeficient patients. Although cryptococcal disease is one of the major causes of death in HIV-
infected patients, especially in sub-Saharan Africa, not all patients at risk with low CD4 counts develop the disease. It has been
thus hypothesized that host genetic variation may represent an important susceptibility risk factor for this infection. In their
recent study inmBio, Rohatgi et al. [S. Rohatgi et al., mBio 4(5):e00573-13, 2013, doi:10.1128/mBio.00573-13] present an impor-
tant piece of evidence to support this hypothesis, by demonstrating that the FCGR3A 158 F/V polymorphism has an important
impact on susceptibility to cryptococcal disease in HIV-infected patients. The authors present both genetic evidence and immu-
nological validation for the hypothesis that humoral immunity in general and FCGR3A-mediated uptake and antibody-
dependent cellular cytotoxicity (ADCC) in particular play important roles in the pathogenesis of Cryptococcus infection. Their
discovery that the 158V allele of this polymorphism can increase the risk of Cryptococcus infections up to 20-fold in homozygous
individuals opens the possibility for risk stratification and personalized treatment of HIV-infected patients.
Cryptococcus species represent major fungal pathogens in hu-mans. Twomajor species of Cryptococcus previously classified
as varieties of the same species have been discerned recently,Cryp-
tococcus neoformans and Cryptococcus gattii, which share many
characteristics but also display differences in theirmicrobiological
and epidemiological properties (1). C. neoformans can be further
subdivided into two varieties:Cryptococcus neoformans var. grubii,
which enjoys a global distribution, and Cryptococcus neoformans
var. neoformans, which is found most often in Europe (2). While
cryptococcal infections affect both immunologically competent
and compromised individuals, the prominence of Cryptococcus in
human pathology has been largely due to HIV: indeed,Cryptococ-
cus infections have been described from the start of the pandemic
as one of the most important complications of AIDS, and they
exact a high toll in terms ofmorbidity andmortality (3). However,
despite the clear importance of CD4-mediated immunity for host
defense against Cryptococcus and the association of CD4 cell loss
and susceptibility to cryptococcal infection, not all HIV-infected
patients with low levels of CD4 cells will develop the disease.
Moreover, CD4-competent individuals also can develop infection
withCryptococcus; hence, other host or environmental risk factors
must influence susceptibility to the infection as well.
A landmark study performed more than 2 decades ago that
assessed mortality due to infectious disease in adult adoptees and
their biological parents revealed a very strong genetic component
in human susceptibility to various infections (4). Despite the
strong possibility that genetic factors impact susceptibility to fun-
gal infections in general and to Cryptococcus infections in partic-
ular, very few studies have investigated these risks until now. In
non-HIV patients, FcR and mannose-binding lectin (MBL)
polymorphisms have been reported to increase susceptibility to
cryptococcal infections (5–7). Paradoxically, much less is known
about genetic factors that influence susceptibility to cryptococcal
disease inHIV-infected patients. The recent study byRohatgi et al.
(8) represents an important first step in that direction by confirm-
ing that the FCGR3A 158V allele, a susceptibility trait in non-HIV-
infected individuals, also increases the risk of cryptococcal disease
in HIV patients. Heterozygous individuals have a 2.1-fold-
increased risk of contracting cryptococcal disease, while the ho-
mozygous individuals display a 21-fold-increased susceptibility to
the infection (8). In contrast, no association between the FCGR2A
131 H/R polymorphism and cryptococcal disease was observed in
this population of HIV-infected individuals, in contrast to earlier
studies that identified this association in non-HIV-infected Euro-
pean patients (5). Interestingly, this same polymorphism was not
associated with Cryptococcus infections in a Chinese cohort (6),
suggesting that ethnic differences exist in the genetic susceptibility
to cryptococcal infection.
The implications of the study by Rohatgi and colleagues (8) are
2-fold. First, this study confirms the earlier reports that identified
the influence of polymorphisms in FcRs on susceptibility to
Cryptococcus (5, 6) and establishes the importance of antibody-
dependentmechanisms for the pathogenesis of human cryptococ-
cal disease. The authors’ previous in vitro and experimental stud-
ies have suggested a role during the infection for antibody-
mediated recognition and phagocytosis of Cryptococcus (9–11),
and this extends earlier results by other groups (12–14). Now, the
authors extend these observations by the study of the genetic risk
factors for the human infection. Antibody-mediated immunity is
thus demonstrated to play an important, albeit somewhat unex-
pected, role during cryptococcal infection. Second, the study by
Rohatgi et al. (8) takes a first step toward genetic risk stratification
in HIV-infected individuals, with homozygous HIV-infected pa-
tients displaying amore-than-20-fold-increased risk for infection.
This very significant increase in the risk of infection, if confirmed
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in future validation cohorts, may justify the identification of at-
risk individuals and an intensified prophylactic approach to cryp-
tococcal infections in HIV-infected individuals.
Additional studies are warranted to validate the findings of
Rohatgi et al. (8). The cohort in this study was relatively small and
homogeneous, so it is necessary to assesswhetherFCGR3A 158V is
associated with a high risk for Cryptococcus infection in other
HIV-positive populations aswell. Genetic validation in a cohort of
patients with both genders is also needed, as the cohort investi-
gated by Rohatgi et al. (8) consisted of males only. On the other
hand, the authors partially compensated for the lack of a genetic
validation study through functional assays aimed at identifying
the biological mechanism behind the effects of the FCGR3A poly-
morphism on susceptibility to the disease. The authors demon-
strate that the risk 158V allele is associatedwith an increased bind-
ing of the receptor to Cryptococcus-IgG complexes and a
potentiation of NK-dependent antibody-dependent cellular cyto-
toxicity (ADCC). They propose that the increased uptake ofCryp-
tococcus contributes to a “Trojan horse”-like spread of the fungus
through infected macrophages, while the increased inflammatory
reaction may contribute to the damage of the blood-brain barrier
and dissemination of the infection to the brain. These are impor-
tant and persuasive functional insights that contribute to our un-
derstanding of the disease. Nevertheless, additional experimental
studies are needed to further validate this hypothesis in vivo.
The approach of the authors not only to identify a genetic risk
factor but also to explain the biological mechanisms behind it is
commendable. This is desirable in more genetic studies, in which
often only statistical significance is sought, without trying to iden-
tify the functional implications of genetic risk factors. The ap-
proach to obtain complementary genetic and functional data not
only gives the chance to understand better the pathophysiology of
the disease but at the same time opens the possibility of creating
novel diagnostic and/or therapeutic strategies.
In conclusion, the interesting study by Rohatgi and colleagues
(8) represents a first step toward uncovering the genetic suscepti-
bility to Cryptococcus infections in HIV-infected individuals. The
study identifies the FCGR3A 158V allele as an important risk fac-
tor for the infection, opening the possibility for risk stratification
in patients with advanced HIV infection. As a researcher, I hope
that this investigation will embolden the community studying
fungal infections to continue and extend these observations. Re-
cruitment of additional and larger cohorts and genetic studies
based on both hypothesis-driven and discovery-driven ap-
proaches (genome-wide association studies), as well as functional
validation studies, are all needed in order to address the major
clinical challenge represented by Cryptococcus infections.
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